Here is a gift for the Holidays from a likely forthcoming book I am considering releasing, titled
Bolus: A Science-Based Guide to recombinant human Growth Hormone (rhGH) for the Athlete, Aesthete, and Aging Gym-goer
This protocol is in direct contravention of the commonly touted 3-5x daily injections of rhGH for lipolysis and the use of GH+fasted cardio for fat loss.
rhGH for lipolysis
Author: Type-IIx
Daily exercise:
Morning or daytime bolus ideally 2-3 hr pre-workout
Single large bolus (≥3IU) for lipolysis: [6] showed lipolysis (blood 3-hydroxy-butyrate) was positively correlated to the peak hGH concentration (r=0.65) for the highest dose (6mcg/kg); [40] showed a significant correlation between the peak GH response to exercise and the post-exercise rise in glycerol measured as area under the curve (r= 0.57,p< 0.04). Also, [69] showed that a single s.c. bolus versus two promotes nighttime FFA liberation.
meal post-workout (4-4.5hr post-bolus), see FFA liberation:
View attachment 157904
FFA liberation: FFA liberation follows an oscillating, rhythymic pattern for 24 hr post-bolus (palmitate [glycerol] flux)
- Post-5IU rhGH administration subcutaneous vs. jet-injected
The normal 24-hour pattern of FFAs is characterized by high values prior to a meal and low levels post-meal [68]
[5]
________________________
References:
[5] Verhagen, A., Ebels, J. T., Jonkman, J. H. G., & Dogterom, A. A. (1995). Pharmacokinetics and pharmacodynamics of a single dose of recombinant human growth hormone after subcutaneous administration by jet-injection: comparison with conventional needle-injection. European Journal of Clinical Pharmacology, 49(1-2). doi:10.1007/bf00192361
[6] Hansen, T. K., Gravholt, C. H., Ørskov, H., Rasmussen, M. H., Christiansen, J. S., & Jørgensen, J. O. L. (2002). Dose Dependency of the Pharmacokinetics and Acute Lipolytic Actions of Growth Hormone. The Journal of Clinical Endocrinology & Metabolism, 87(10), 4691–4698. doi:10.1210/jc.2002-020563
[40] Wee, J., Charlton, C., Simpson, H., Jackson, N. C., Shojaee-Moradie, F., Stolinski, M., … Umpleby, A. M. (2005). GH secretion in acute exercise may result in post-exercise lipolysis. Growth Hormone & IGF Research, 15(6), 397–404. doi:10.1016/j.ghir.2005.08.003
[68] Laursen, T., Jergensen, J. O. L., & Chrlstiansen, J. S. (1994). Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults. Clinical Endocrinology, 41(3), 337–343. doi:10.1111/j.1365-2265.1994.tb02554.x
[69] Jørgensen, J. O. L., Møller, J., Møller, N., Lauritzen, T., & Christiansen, J. S. (1990). Pharmacological Aspects of Growth Hormone Replacement Therapy: Route, Frequency and Timing of Administration. Hormone Research, 33(4), 77–82. doi:10.1159/000181589
_______________________
For those interested in the book, its table of contents (so far) is:
- Objective
- Abbreviations
- Research primer: A 'How To' on interpretation of research
- Contraindications
- Skeletal muscle growth and function
- Skeletal muscle: An endocrine organ
- Hypertrophy
- Mechanisms in hypertrophy
- Conclusions regarding skeletal muscle hypertrophy
- Hyperplasia
- Adult myogenesis
- Satellite cells
- Local mIGF-I and Systemic cIGF-I
- Nitrogen balance and reduced AA proteolysis
- Lipolysis
- Mechanisms in lipolytic activity
- Collagen synthesis
- Collagen Type I & Collagen Type III
- Bone density
- Musculotendinous injury recovery and prevention
- Post-immobilization and post-rehabilitation
- Cognitive function
- Anticatabolism
- Cardiorespiratory endurance
- Anaerobic capacity
- Sprint performance
- Metabolic parameters
- LDL reduction
- Anti-aging and rhGH
- Age-related decline in GH
- Studies
- Lipolysis in elderly
- IGFBPs
- IGFBP-1
- IGFBP-2
- IGFBP-3
- IGFBP-4
- IGFBP-5
- IGFBP-6
- Interindividual variation
- IGF-I/IGFBP-3 ratio
- GHBPs
- Genetic polymorphisms
- d3-GHR
- Women and rhGH
- Plot of IGF-I response to rhGH in adult GHD patients by gender
- Dose-response for women vs men
- Cessation
- Blood pressure
- Pulse pressure
- Intracranial hypertension, i.e., headaches
- Obstructive sleep apnea
- Long-term administration
- Strength
- Withdrawal
- Decrement in serum IGF-I
- Effects on thyroid function
- Anthony Roberts' Article "Thyroid Hormone + Growth Hormone – If You Aren’t Using T4 with Your GH, You’re Not Doing It Right"
- Effects on adrenocortical system
- Organ growth
- Pharmacokinetics & Pharmacodynamics
- SubQ serum GH profile
- IM serum GH profile
- Pulsatile serum GH profile
- GH kinetics
- Effects of estradiol-estrogen, obesity
- Effects of testosterone and aromatizable androgens
- Time-course of changes in response to rhGH administration
- Transient negative feedback inhibition
- cIGF-I changes with administration, withdrawal
- Clinical relevance of cIGF-I
- Practical
- Risk-reward balancing
- Dosages and administration
- Conversion of mcg <=> IU
- General instructions for pharmaceutical rhGH preparations
- Specific products and dosages
- Norditropin
- Genotropin
- Serono Serostim
- Humatrope
- Biodenticals
- Cinnatropin, Jintropin, Kigtropin, Hygetropin
- Generics
- Purity variance within a single batch
- French Testing Group
- Practical protocols
- rhGH for lipolysis
- rhGH for hypertrophy
- Primary RT mode drivers of augmented SC fusion
- combined rhGH and Insulin
- rhGH for musculotendinous healing and post-rehabilitation injury recovery
- combined rhGH and rIGF-I
- rhGH for anti-aging
- Permutations based on limited quantity
- Non-rehabilitative usage
- rhGH for anti-aging
- Testing
- Serum IGF-I
- Analytic laboratory quantitative analysis
- rhGH solutions- What is in the vial or pen?
- Antimicrobial preservative agents
- Considerations
- Theoretical
- Dual Effector Hypothesis supersedes the Somatomedin Hypothesis
- Hyperplasia of skeletal muscle
- Molecular signalling
- AR nongenomic pathway
- Modern theory of 22kDa GH binding at the GHR
- Substrate metabolism
- IGF-I, a myokine promoting a local effort for a global effect
- Pathways and natural pulsatile secretion
- β-adrenergic agonists inhibit GH secretion
- Obesity & rhGH
- Gynecomastia
- Glucose metabolism and insulin resistance
- Hyperglycemia
- Metformin
- Downsides of Metformin
- Insulin
- Rapid-acting, -R type
- Slower-acting, -Log type
- Insulin resistance
- TUDCA
- Calcium levels- hypercalcinemia or hypercalciuria
- Edema and water retention
- Tumor growth and risk of carcinogenesis
- Relevant measures
- Natural baseline measures
- GH
- cIGF-I
- Serum T₄
- Monitoring of rhGH course
- HbA1c and blood glucose monitoring
- Interactions with other drugs or exogenous hormones
- AAS
- AAS Effects on IGFBPs and negative inhibition
- Exogenous Testosterone
- Fluoxymesterone
- Stanozolol
- Oxandrolone
- 5α-DHT
- Metformin
- Estrogen
- Alcohol
- Interactions with endogenous hormones
- Thyroid hormones: TSH, T3, T4
- Testosterone
- Prolactin
- Progesterone
- Health conditions that affect rhGH efficacy
- Related
- Growth hormone secretagogues, i.e. "peptides"
- Secretagogues and obesity